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IL-2 is a well-characterized lymphokine that is responsible for growth ordifferen-
tiation oflymphocytes. Intracellular signalings induced by IL-2 are transmitted via
the surface IL-2R with a high affinity to IL-2 (1-3). The high affinity IL-2R has
been demonstrated to be composed ofat least two distinct subunits, IL-2Rp55 and
IL-2Rp75, each ofwhich contains an IL-2 binding site (4-8). IL-2Rp55, with a
molecular weight of55 x 103, is a so-called Tac antigen that has been defined by
mAbs (9-11) and by its gene (12, 13), and does not seem to contain any functional
domain for signal transduction. IL-2Rp75, with molecularweights of 7-75 x 103,
has been detected by chemical crosslinking with 125I-labeled IL-2 (4-8). There is
increasing evidence that the function of signal transduction is associated with IL-
2Rp75. IL-2 has induced intracellular signals for the stimulation ofcell growth (14-16)
and phosphorylation of cellular proteins (17) in cells expressing IL-2Rp75 but not
in those expressing IL-2Rp55 alone (14-16). Furthermore, the internalization ofIL-
2 was mediated by the high-affinity IL-2R or IL-2Rp75 but not by the low affinity
IL-2R, IL-2Rp55 (18-20). Therefore, it is obvious that IL-2Rp75 can induce intra-
cellular signals. However, the molecular nature of IL-2Rp75 and the mechanisms
ofsignal transduction from IL-2R are still unknown. Forinvestigation ofthese sub-
jects, therefore, preparation of an mAb specific for IL-2Rp75 is desirable.
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Materials and Methods
Cell Lines and mAbs.
￿
The cell lines used here were sevenhuman IL-2R' T cell linescar-
ryinghumanTcell leukemia virustype I(HTLVI) (21); TL-Mor, MT2, HUT102, ILTHir,
ILTMat, TL-Hir, and MT-1, two nonhuman IL-2R' T cell lines; Gibbon ape MLA144
and murine CTLL-2, and three human IL-2R- cell lines; MOLT-4, Jurkat and HL-60.
MT-2C41 is a subclone of MT-2, which expresses a large amount of the IL-2R. ILTHir,
ILTMat, and CTLL-2 were maintained in RPMI-1640 medium supplemented with 10%
FCS 2 HIM L-glutamine, antibiotics, and 1 nM human rIL-2 (obtained from Shionogi Co.,
Osaka,Japan). Theothercell lineswere maintained in theRPMI-1640medium without IL-2.
mAbs used as controls were two IgG1 mAbs specific for IL-2Rp55, H-31, and H-48 (10,
11), and aIgG1 mAb, y-481, specific for the Sendai virus (provided by Dr. Tozawa, Kitasato
University, Sagamihara, Japan).
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Preparation ofa Hybridoma Producing an mAb.
￿
BALB/c mice were immunized intraperitoneally
with 10' TL-Mor cells per mouse four times at weekly intervals. The TL-Mor cellsused for
immunization were pretreated with 1.0 ml sera of BALB/c mice hyperimmunized with three
humancell lines negative for IL-2R: MOLT4, HPB-Null, and HL-60. The sensitizedspleen
cells were fused with a mouse myeloma cell line, SP2/0-Ag14, and hybridoma cell clones were
obtained as described previously (22). More than 75,000 clones were screened for production
of antibody by IL-2 binding blocking assays firstly with TL-Mor cells bearing IL-2Rp55
and IL-2Rp75 on microplates with vigorous washing, and secondly with MT-1 cells bearing
only IL-2Rp55 in microtubeswith sucrose cushion as reported previously (11, 18). One clone
producing an mAb that blocked the IL-2 binding to TL-Mor cells, but not to MT-1 cells,
was isolated and recloned. Finally, the hybridoma cell line, derived from a single cell, was
established and named TU27 . The class of antibody produced by TU27 is IgG1 .
Binding Assay ofIL-2 and TU27 mAb.
￿
Human rIL-2 and purified TU27 mAb were radio-
labeled with Na1211 (Amersham Corp., Arlington Heights, IL) by the chloramine T method,
and their binding assays for various cells were performed as described previously (11, 18).
In brief, 106 cells were incubated with '251-IL-2 (1.5 x 106 dpm/pmol) or '251TU27 mAb
(4 x 106 dpm/pmol) for 1.5 h at 4°C. The radioactivities in the supernatant and cells were
measured separately. Their bindings were analyzed by Scatchard plots.
For 1211-IL-2 binding blocking assays with mAbs, the cells were pretreated with 50 hg/ml
ofmAb in RPMI-1640 medium containing 1 17c BSA, 25 mM Hepes and 0.02 % sodium azide
for 1 h at 4°C before addition of IL-2 .
Inhibition of TU27 mAb Binding by IL-2.
￿
106 MT2C41 cells were incubated with various
concentrations of IL-2 in 50 jl of RPMI-1640 medium containing 1% BSA, 25 mM Hepes,
and 0.02% sodium azide at 4°C for 30 min, and then treated with 50 JAI of 1 nM 125ITU27
mAb at 4°C for 1 h. The cells were precipitated in microtubes with 1 M sucrose cushion
by centrifugation. The radioactivity associated with cells was counted and the number of
binding sites of TU27 mAb was calculated from its specific radioactivity.
Affinity Labeling of Cells with 1251-IL-2.
￿
Affinity labeling of cells with 1251-IL-2 was per-
formed as reported previously (18). In brief, 10' cells were preincubated for 1 h in the pres-
ence of 50 hg/ml of mAbs or 180 nM unlabeled IL-2 and further incubated with 0.1 nM
or 5 nM 1251-IL-2 for 1 h on ice. The cells were then treated with a chemical crosslinker,
disuccinimidyl suberate (DSS Pierce Chemical Co., Rockford, IL), as reported by Sharon
et al. (4). The DSS-treated cells were solubilized in lysis buffer (300 nM NaCl, 50 mM Tris-
HCI [pH 7 .4] and 0.5% NP-40) . Then the cell lysates were sujected to 7 .5% SDS-PAGE.
Radioimmunoprecipitation .
￿
2-4 x 10' cells were radiolabeled with Na1251 by using iodina-
tion reagent (IODO-GEN; Pierce Chemical Co.) as described previously (23). The radiola-
beled cells were solubilized in 2 ml of buffer (25 mM Tris HCl [pH 7.5], 140 mM NaCl,
1 mM EDTA, 2 mM PMSF, 0.1% aprotinin, 0.5% NP-40), and appropriate aliquots were
incubated with mAbs for 6 h. Then they were incubated with protein A-Sepharose pretreated
with anti-mouse IgG for 4 h at 4°C. Immunoprecipitates bound to protein A-Sepharose were
analyzed by 10% SDS-PAGE as described previously (23).
Incorporation of [3H]Thymidine.
￿
IL-2-dependent ILTMat cells were washed three times
with PBS, then preincubated for 8 h in the medium without IL-2, and delivered into 96-well
microplates. Subsequently, mAb was added at a concentration of 50 l~g/ml, and then IL-2
diluted serially was added to the wells. The cells were incubated for 24 h at 370C under 7%
C02 in air. During the last 4 h of incubation 1 ACi of [3H]TdR was added to each well. The
incorporated [3H]TdR was counted as described elsewhere (24) .
Results
Cell lines were examined for the numbers of sites of high- and low-affinity IL-2R
for IL-2 binding, and then for the numbers of binding sites ofTU27 mAb by Scatchard
plot analyses. The results are shown in Table I . In all the cell lines bearing high-
affinity IL-2R, the numbers of TU27 mAb binding sites were similar to those of
high-affinity IL-2R. In MLA144 cells, which have been shown to express only IL-TAKESHITA ET AL.
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TABLE I
Binding Sites of TU27 mAb andSites of High- and Low-affinity IL-2R
Scatchard plot analyses for IL-2 and TU27 mAb bindings were performed as
described in Materials and Methods.
UD, undefined.
2Rp75 with an intermediate affinityto IL-2 (5), the numberofTU27 mAb binding
sites was also similar to that of IL-2 binding sites. On the other hand, the TU27
mAb binding site was undetectable on MT-1 and TL-Hir cell lines, which bear only
IL-2Rp55, and on three human Tand monocytic cell lines, MOLT4, Jurkat, and
HL-60, whichare negative forIL-2R. A murine IL-2-dependent Tcellline, CTLL-
2, bearing both high- and low-affinity IL-2R, did not react with TU27 mAb either.
These results indicate that TU27 mAb recognizes the antigen expressed on surfaces
of human and Gibbon ape T cell lines bearing IL-2Rp75.
The molecular mass ofthe antigen for TU27 mAb was determined by the SDS-
PAGE ofradioimmunoprecipitation (Fig. 1). TU27 mAb immunoprecipitated mol-
ecules with molecular masses of71-81 kD (N75 kD) from lysates of1251-labeled ILT
Mat, PHA-treated PBL, TL-Mor, MLA144, and MT-2 cells butnotTL-Hir,Jurkat,
andCTLL-2 cells, whereas H-31 mAb detected abandwith an approximate molec-
ular mass of 55 kD in the lysates of cells positive for IL-2Rp55, such as ILTMat
and PBL cells.
To define further specificity ofTU27 mAb, its effects on the IL-2 binding to cells
were examined by chemical crosslinking with 1251-IL-2. MLA144, MT2, and TL-
Hircells preincubated in the presence or absence ofTU27 mAb, H-31 mAb, y-481
mAb, or unlabeled IL-2 were further incubated with 1251-IL-2, and then treated
with a chemical crosslinker, DSS. The cell lysates were analyzed by the SDS-PAGE
followed by autoradiography (Fig. 2). TU27 mAb completely blocked the bindings
of 1251-IL-2 to the IL-2Rp75 ofMLA144 and to IL-2Rp75 and IL-2Rp55 ofMT-2
cells, but not the bindings to the IL-2Rp55 of TL-Hir cells. On the other hand,
H-31 mAb specific for IL-2Rp55 completely blocked the binding to the IL-2Rp55
but not the IL-2Rp75 of these cells. As a control, unlabeled IL-2 blocked all the
bindings of 1251-IL-2 to IL-2Rp55 and IL-2Rp75 .
Cell lines
IL-2R
Low-affinity
(sites/cell)
High-affinity
Binding of TU27 mAb
(sites/cell)
TL-Mor 519,000 6,500 5,000
MT-2 620,000 6,300 4,800
MT-2C41 1,700,000 21,000 15,700
HUT102 457,000 3,500 1,900
MT-1 372,000 <100 UD
TL-Hir 208,000 <100 UD
ILT-Hir 140,000 2,800 1,400
ILT-Mat 128,000 3,300 1,700
MLA144 1,600 UD 900
MOLT-4 UD' UD UD
Jurkat UD UD UD
HL-60 UD UD UD
CTLL-2 752,000 2,400 UD1326
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FIGURE 1 .
￿
Immunoprecipitation of 125I -labeled cell lysates with mAbs. Surfaces of cells indi-
cated was labeled with Na 125I, and their lysates were indirectly precipitated by TU27 mAb (a),
.y-481 mAb as a negative control (6), and H-31 mAb (c) . Immunoprecipitates were analyzed by
10% SDS-PAGE . PBL were stimulated withPHA for 1 d and then incubated with IL-2 for 2 d .
Furthermore, a Scatchard plot analysis of the IL-2 binding was performed in the
presence ofTU27 mAb, H-31 mAb, or H-48 mAb(Fig. 3) . MT2C41 cells expressed
both high affinity IL-2R (Kd = 57 pM, 2.1 x 104 sites/cell) and low-affinity IL-2R
(Kd = 38 nM, 1.7 x 106 sites/cell) . TU27 mAb completely blocked IL-2 binding
to the high-affinity IL-2R but not to the low-affinity IL-2R . The low-affinity IL-2R
detected in the presence of TU27 mAb was calculated at 2.1 x 106 sites/cell and
47 nM of Kd, which were not significantly different from those detected in the pres-
ence ofcontrolmAb. H-31 mAb, on theotherhand, completely blocked IL-2 binding
to both the high- and low-affinity IL-2R, but the intermediate-affinity IL-2R (Kd
= 3.4 nM, 1.7 x 104 sites/cell) became detectable in the presence of H-31 mAb .
Furthermore, the effect of IL-2 on 12'ITU27 binding to MT=2C41 cells was also ex-
amined (Fig. 4) . When MT-2C41 cells were preincubated with IL-2, the
1211TU27
mAb binding to the cellswas blocked dose dependentlyby IL-2 . 1.0nM IL-2 almost
completely inhibited the
1211TU27 mAb binding . These observations suggest that
TU27 mAb recognizes an epitope located near to the IL-2 binding site of IL-2Rp75,
resulting in blocking of 1251-IL-2 binding to IL-2Rp75 and impeding the composi-
tion of the high-affinity IL-2R .
Next, the effects ofTU27 mAb on growth of IL-2-dependent ILTMat cells wereFIGURE 2 .
￿
Effects ofTU27 mAb on affinity-labeling of 1251-IL-2 . Cellswere incubated for 1 h
in the presence of y-481 mAb (a), TU27 mAb (b), H-31 mAb (c), or unlabeled IL-2 (d) . Subse-
quently, MLA144 and TL-Hir cells were incubated with 5 nM I25I-IL-2 and MT-2 cells with
0.1 nM I25I-IL-2 . Their lysates were analyzed by 7.5% SDS-PAGE .
Bound IL-2 molecules per cell (x10 -5 )
FIGURE 3 . Effects of TU27
mAbon Scatchard plot analysis
of I25I-IL-2 binding . MT-2C41
cells were treated with TU27
mAb ("), H-31 mAb (A), or
H-48 mAb (p) and untreated
(O) for 1 h at 4°C . They were
then incubated with 1211-IL-2
for 1.5 h at 4°C . Bindings of
I25I-IL-2 were analyzed by
Scatchard plot .1328
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￿
Inhibition of 1251TU27 mAb
bindingby Il-2 . MT2C41 cells were incubated
with indicated dosesofIL-2 in 50 j1 medium
at 4°C for 30 min, and then volumes of 50
wl of 1 nM 1251TU27 mAb were added to
each well, andcellswere incubated at 4°C for
1 h. The number of cells bound 1251TU27
mAbmoleculeswasdetermined as described
in Materials and Methods.
FIGURE 5.
￿
Effects of TU27 and H-31 mAbs on
[3H]TdR incorporation of IL-2-dependent cells. IL-
2-induced incorporationof [3H]TdRwas assayed for
IL-2 dependentILTMatcells in the absence (O)or
presence of50 ttl/ml of TU27 mAb ("), H-31 mAb
(A), .y-481 mAb ([I), and a combination of TU27
and H-31 mAbs (A).
examined by the [3H]TdR incorporation assay in the presence of various concen-
trations of IL-2 from 0 to 100 U/ml, and were compared with those of H-31 mAb
(Fig. 5). TU27 mAb partially inhibited the growth of ILTMat cells at low concen-
trations of IL-2, <11 U/ml. At a concentration of 1 U/ml of IL-2, ILTMat growth
was inhibited up to 80 17o in the presence of concentrations of TU27 mAb from 11
to 100 ug/ml(Fig. 6). Growth inhibition of50% wasseen at 2ttg/ml ofTU27. Whereas
H-31 mAb completely inhibited the growth at the low concentrations of IL-2, and
partially inhibited at 11 and 33 U/ml of IL-2, but little inhibited it at 100 U/ml of
IL-2 . However, combination of TU27 and H-31 mAbs induced almost complete in-
hibition of growth in the whole range of IL-2 doses (Fig. 5).0
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FIGURE 6.
￿
Dose-dependent effect ofTU27 nnAb on
IL-2-induced [sH]TdR incorporation of ILTMat
cells. IL-2-induced incorporation of [3H]TdR of IL-
2-dependent ILTMat cells was determined in the
presence of indicated doses of TU27 mAb (O) or
y-481 mAb (EI). Cells were cultured in the presence
of IL-2 at a concentration of 1 U/ml.
Discussion
We havejust established a mouse hybridoma cell line, TU27, producing an mAb
that specifically recognizes human and Gibbon ape IL-2Rp75 as defined by the fol-
lowings. TU27 mAb reacted with all the cell lines bearing IL-2Rp75 tested, except
a murine T cell line, CTLL-2 . The number ofTU27 mAb binding sitse was similar
to that of high-affinity IL-2 binding sites. In SDS-PAGE analysis, TU27 mAb de-
tected a cell surface molecule with an approximate molecular mass of 75 kD. Fur-
thermore, TU27 mAb completely blocked the binding of 1251-IL-2 to IL-2Rp75 but
not IL-2Rp55. Vice versa, IL-2 also completely blocked the binding of 1251TU27
mAb to cells bearing IL-2Rp75 .
There are at least tnree bands that can be detected by the 1251-IL-2 affinity
labeling and crosslinking method; they are the 55-kD molecule of IL-2Rp55, and
the 75- and 70-kD molecules of IL-2Rp75 (7, 25). MLA144 and YT cellsare known
to express the 75- and 70-kD molecules but not the 55-kD molecule, although the
75- and 70-kD molecules have often been detected as one band (4-6). TU27 mAb
immunoprecipitated a 75-kD molecule but not 70-kD molecule, which suggested a
possibility that the 75-kD molecule is antigenically different from the 70-kD mole-
cule, although it is still unclear whether these two molecules are related to each other
in any way. The present study also suggested that the 75-kD molecule of IL-2Rp75
has an IL-2 binding site. However, we have not obtained any direct evidence that
the 75-kD molecule precipitated with TU27 mAb was autophosphorylated (data
not shown), suggesting that the 75-kD IL-2R molecule could be distinct from the
class of receptors containing a tyrosine kinase.
It has been considered that the IL-2-mediated growth signal is transduced from
the high-affinity IL-2Ror the intermediate-affinity IL-2R but not from the low-affinity
IL-2R, and that the IL-2Rp75 composing the high- and intermediate-affinity IL-
2R is crucial for signal transduction (14-18, 20). As TU27 mAb blocked IL-2 binding
to IL-2Rp75 and to high-affinity IL-2R but not to low-affinity IL-2R, it was sus-
pected that TU27 mAb inhibits IL-2-dependent growth ofcells or that it stimulates
cell growth as an agonist of IL-2 . The IL-2-dependent growth of ILTMat cells was
significantly inhibited by TU27 mAb at low concentrations of IL-2, <11 U/ml, but
not at high concentrations of IL-2, although the combination of TU27 and H-311330
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mAbs specific for IL-2Rp55 induced complete inhibition of it in the whole range
of IL-2 doses up to 100 U/ml. In spite of the complete blocking of IL-2 binding
to high-affinity IL-2R by TU27 mAb in the Scatchard plot analysis, TU27mAb did
not completely inhibit the IL-2-dependent cell growth. This suggests two possibili-
ties . One is that a differenceexists in the ability ofTU27 mAb to block IL-2 binding
between the Scatchard plot analysis at 4°C and the [3H]TdR incorporation assay
at 37°C. Under the latter condition, IL-2Rp75, which can be newly synthesized,
may bind IL-2 associated with IL-2Rp55 to compose the high-affinity IL-2R. In
such a case, TU27 mAb would not be able to block the IL-2 binding because of
its lower binding affinity (Kd = 2 .1 nM) to the high-affinity IL-2R (Kd = 28 pM)
which could be efficiently composed of a large amount of IL-2 associated with IL-
2Rp55 expressed on cell surface. The otherpossibility is that the IL-2-mediated growth
signal could be transduced not only from the high-affinity IL-2R but also from the
low-affinity IL-2R of ILTMat cells in the presence ofTU27 mAb. There is a report
describing that L cells transfected with the IL-2Rp55 gene were stimulated to incor-
porate [3H]TdR by IL-2 (26), although IL-2 has not been found to induce any in-
tracellular signaling in cell lines expressing only the low-affinity IL-2R, IL-2Rp55,
in other reports (17, 27, 28). To determine which of the above possibilities for signal
transduction from IL-2R, further characterization of the molecular nature of IL-
2Rp75 is required. Our new mAb, TU27 mAb, should be useful for such studies.
Summary
A mouse hybridoma cell line, TU27, producing an mAb was established. TU27
mAb reacted with various human and Gibbon ape T cell lines bearing the IL-2R
p75 (IL-2Rp75), but not with cell lines expressing only Tac antigen, IL-2Rp55, and
numbers of its binding sites on cell surfaces were similar to those of high-affinity
IL-2R. Radioimmunoprecipitation with TU27 mAb defined a molecule with a mo-
lecular mass of 75 kD on the surface of IL-2Rp75 bearing cells. TU27 mAb com-
pletely blocked IL-2 binding to IL-2Rp75 and to the high-affinity IL-2R but not
to IL-2Rp55 composing the low-affinity IL-2R. The IL-2-dependent growth of a
human T cell line, ILT Mat, was significantly inhibited by TU27 mAb only at low
concentrations of IL-2, and combination of TU27 mAb and H-31 mAb specific for
IL-2Rp55 completely inhibited the cell growth even at high concentrations of IL-2.
These data strongly suggest that TU27 mAb is specific for the human IL-2Rp75.
Receivedfor publication 28 September 1988 and in revisedform 29 December 1988.
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